Veridas Takes the Lead in the Race Against Gen AI Fraud with New Advanced Injection Attack Capability
Generative AI is fueling a new wave of identity fraud, making digital security more critical than ever. In response, Veridas, a global leader in AI-driven identity verification, has introduced an advanced injection attack detection capability to combat the growing threat of synthetic identities. This new feature strengthens fraud prevention by combining injection detection with liveness verification across face, voice, and document authentication.
Injection Attacks: The Hidden Threat in Digital Fraud
According to the Veridas Identity Fraud Report 2024, 85% of financial fraud cases now involve synthetic identities. The UK government recently declared deepfakes as the ‘greatest challenge of the online age’, highlighting these growing risks. Fraudsters inject deepfakes and synthetic data directly into identity systems—bypassing device sensors entirely. Traditional fraud detection only analyzes what’s presented (images, videos, or voices), not whether the device is compromised. Veridas has focused onPresentation Attack Detection (PAD), which detects fake images, videos, and voices. Now, we go further by ensuring the integrity of the device itself. Our new injection attack detection prevents fraud at its source, securing both the biometric input and the device it comes from.
Injection attacks pose a significant risk to millions of users and businesses. Traditional fraud prevention is no longer enough, and innovative solutions are needed to address these advanced threats.
Veridas’ Breakthrough: Advanced Injection Fraud Detection
For years, Veridas has been at the forefront of secure onboarding solutions, excelling in document verification, selfie authentication, and liveness detection. Now, with the introduction of its advanced injection attack detection feature, Veridas is taking fraud prevention to the next level.
This new security feature verifies device authenticity during onboarding to combat AI-driven injection attacks. Leading financial institutions in Italy, Spain, the US, and Mexico are already using it to uncover previously undetected fraud attempts.
“Our technology is a game-changer for businesses facing the challenges of Gen AI fraud. By adopting Veridas’ injection fraud detection, companies can protect their operations, maintain customer trust, and confidently meet compliance requirements,”said Javier San Agustín, CTO at Veridas.
About Veridas
Veridas is a global provider of advanced identity verification, biometrics, and anti-fraud solutions. Its end-to-end services enable organizations across sectors to build secure, user-friendly digital experiences.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210557330/en/
Contacts
Juan Campos
PR Manager Veridas
+34 667 245 257
jfcampos@veridas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
![](/data/images/public/58763726/70892360/1281fac5-2b2c-46e0-bbea-4d34ac41e38e-w_780.jpg)
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
comforte AG Warns of Impending March 2025 PCI DSS 4.0 Compliance Deadline11.2.2025 11:41:00 EET | Press release
comforte AG, a global leader in data security, today urged global businesses to finalize their PCI DSS 4.0 plans, ahead of the compliance deadline which falls on 31 March 2025. PCI DSS 4.0 is a major new iteration of the Payment Card Industry Data Security Standard, which applies to any organization which stores, processes or transmits cardholder data. As such, it has an outsized impact on sectors such as financial services and retail. The latest version features over 50 new technical requirements including new rules around data protection mechanisms. A key focus for PCI DSS 4.0 is to encourage cybersecurity as a long-term, continuous process, which is why additional flexibility has been baked into the standard—allowing organizations to choose the security controls most suited to their business. comforte’s tokenization technology is a proven, format-preserving way to safeguard cardholder data in line with PCI DSS 4.0, while preserving data utility. Because sensitive data elements like
Dragon Elements Breaks Free From Screens With LATIDO ® Capsules11.2.2025 11:00:00 EET | Press release
SCALE Nanotech, an advanced R&D company based in Estonia, has announced the launch of its spinout Dragon Elements in Spain, marking a disruptive entry into the XR and wearable electronics sector. Dragon Elements is set to commercialize LATIDO® capsules, a revolutionary graphene-based technology designed to redefine human interaction with hardware by eliminating the need for traditional audio and video components. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211733484/en/ The Birth of LATIDO®: A New Paradigm in Audiovisual Technology Derived from the Spanish word latido (heartbeat), LATIDO® encapsulates a radical shift in audiovisual hardware. Unlike conventional technology that requires separate components for sound and vision, LATIDO® harnesses millions of one-atom-thick graphene membranes to seamlessly control both light and sound within a single monolithic device, removing the need for separate screens or speakers. “
Xsolla and AppsFlyer Unveil Custom Integration to Boost Mobile Game Web Shop Performance11.2.2025 11:00:00 EET | Press release
Xsolla, a leading global video game commerce company, has partnered with AppsFlyer, the global leader in mobile measurement, attribution, and data analytics, in a first-in-the-gaming industry web shop collaboration. This enhancement of the Xsolla and AppsFlyer partnership provides game developers with improved insights and simplified activation for its Web Shop solution, which is available worldwide. It also introduces solutions to address cross-platform measurement and attribution challenges. The partnership includes two integration options: server-to-server (S2S) and web integrations for mobile games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211661118/en/ (Graphic: Xsolla) Xsolla and AppsFlyer have collaborated closely for over a year to develop two custom integrations that address critical challenges in the mobile market. These integrations offer game developers comprehensive data on user behavior, campaign perfo
Knauf Builds an Autonomous Supply Chain With Blue Yonder11.2.2025 11:00:00 EET | Press release
In the highly competitive and dynamic building materials and systems industry, manufacturers need to drive strategic growth and financial performance to succeed. That’s why Knauf, a globally leading manufacturer of building materials and construction systems, has chosen to deploy Blue Yonder Demand Planning, a cloud-native solution with cognitive capabilities that utilizes artificial intelligence (AI) and machine learning (ML). The solution will enable Knauf to gain access to industry-focused insights that enable faster decisioning and more precise forecasting to further transform its supply chain demand planning capabilities. The solution deployment is led by Blue Yonder Professional Services. Since 1932, Knauf has been synonymous with innovation, quality, and sustainability, boasting over 300 production sites in more than 90 countries. The company’s extensive product range – from drywall systems to plaster and ceiling solutions – and innovative insulation materials enables sustainabl
MammaPrint ® Reimbursement Indication Extended in Belgium11.2.2025 09:00:00 EET | Press release
Agendia®, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for MammaPrint® to include its use in the neoadjuvant setting, effective January 1, 2025. The genomic assay will now be available for full reimbursement for patients with HR+/HER2 negative early-stage breast cancer in both the pre- and postoperative settings, enabling testing on core needle biopsies for neoadjuvant treatment decisions—a pivotal advancement in providing patients with the personalized care they require. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210842892/en/ (Graphic: Business Wire) "The ability to now use MammaPrint on core needle biopsy specimen in Belgium represents a significant step for personalized treatment for women battling breast cancer," said Professor Martine Piccart, Honorary Professor of Oncology at the Université Libr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom